ChemoCentryx CCX872 shows significant reductions in liver fibrosis
ChemoCentryx announced the presentation of data from in vivo models of non-alcoholic steatohepatitis, or NASH, with CCX872, a selective orally administered inhibitor of the chemokine receptor known as CCR2, at the American College of Gastroenterology, or ACG, 2016 Annual Meeting, being held October 14-19, 2016. The company's CCR2 inhibitor CCX872 demonstrated significant reductions in liver fibrosis when compared to either placebo or a separate compound which is a dual inhibitor of the chemokine receptors CCR2 and CCR5 currently in clinical development by another party. The data suggest a potential application of CCX872 for the treatment of patients with NASH, a severe type of non-alcoholic fatty liver disease caused by chronic inflammation that can lead to fibrosis of the liver. NASH affects 3%-5% of the U.S. population.